|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
ARID2 mutation always co-occurred with APC mutation, whose tumor variant allele frequency (TVAF) was higher than that of ARID2 in D/IEN.
|
30474112 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
p204, a murine member of the interferon-inducible p200 protein family, and its human analogue, IFI16, have been shown to function as tumor suppressors in vitro, but the molecular events involved, in particular in vivo, remain unclear.
|
29691417 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent genomic studies have identified frequent mutations of ARID2, a component of the SWItch/Sucrose Non-Fermentable (SWI/SNF) complex, in hepatocellular carcinoma, but it is not still understood how ARID2 exhibits tumor suppressor activities.
|
28238438 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We previously showed that the tumor suppressor ARID2 inhibits hepatoma cell cycle progression and tumor growth.
|
28498550 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings highlight the potential role of ARID2 as a tumor growth suppressor in HCC.
|
27351279 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that in addition to ARID1A, which was mutated in 39% of the tumors (18/46), also ARID1B (13%, 6/46), ARID2 (13%, 6/46) and ARID4A (20%, 9/46) were frequently mutated.
|
24382590 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Extension studies using tumors from another 96 patients discovered a large number of truncation mutations in tumor suppressors (TP53 and RB1), protein phosphatases (e.g., PTEN, PTPRB, PTPRD, and PTPRT), as well as chromatin remodeling genes (e.g., ASXL3, MLL2, and ARID2).
|
25393105 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our recent work described novel inactivating mutations of ARID2 (AT-rich interactive domain 2) in four major subtypes of HCC through exomic sequencing of ten HCV-associated HCCs and subsequent evaluation of the tumors from additional affected individuals.
|
22095441 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, 18.2% of individuals with HCV-associated HCC in the United States and Europe harbored ARID2 inactivation mutations, suggesting that ARID2 is a tumor suppressor gene that is relatively commonly mutated in this tumor subtype.
|
21822264 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This observation, along with the myeloid immunophenotype of the tumor and, at least in one case, the patient's correspondingly good response to alpha-interferon therapy, suggests that p200 BCR-ABL is more similar to p210 BCR-ABL, in which the DH, CDC24 and PH domains are all maintained, than to p185, in which these domains are all lost.
|
12091118 |
2002 |